BRCA-1

Tamoxifen helps lower risk of new breast cancer in BRCA mutation carriers, too

Since the 1970s, tamoxifen (developed by AstraZeneca) has been shown to prevent breast cancer recurrence secondary prevention in women who were surgically treated for a primary tumor. The drug is an estrogen-receptor modifier,